CryoCath Surgifrost
This article was originally published in The Gray Sheet
Executive Summary
Surgical cryoablation system will debut in July following recent 510(k) clearance received by strategic partner Endocare for treatment of cardiac arrhythmias in patients undergoing other cardiac procedures such as bypass surgery and valve replacement. The firm sees a $200 mil. market opportunity...
You may also be interested in...
CryoCath Looks To Ice Atrial Fibrillation, Flutter With Cryoablation Therapies
CryoCath aims to place its Freezor cryoablation catheter in 300 centers by year-end, pending PMA approval of the supraventricular tachycardia treatment device
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.